This is a working overview of GRF(1-29), written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
==== MeSH D06.472.759 – placental hormones ==== MeSH D06.472.759.367 – chorionic gonadotropin MeSH D06.472.759.367.125 – chorionic gonadotropin, beta subunit, human MeSH D06.472.759.367.562 – glycoprotein hormones, alpha subunit MeSH D06.472.759.451 – gonadotropins, equine MeSH D06.472.759.692 – placental lactogen
Ivermectin/albendazole is indicated for use in people aged five years of age or older, for the treatment of soil-transmitted helminth infections, caused by different types of intestinal parasitic worms, which are spread through soil contaminated by human feces in areas with poor sanitation. Among the worms responsible for these diseases are hookworms (Ancylostoma duodenale, Necator americanus), roundworms (Ascaris lumbricoides), whipworms (Trichuris trichiura) and a roundworm called Strongyloides stercoralis. Ivermectin/albendazole is also indicated for the treatment of microfilaraemia (the presence of worm larvae in the blood) in people with lymphatic filariasis. Lymphatic filariasis is a neglected tropical disease commonly known as elephantiasis, which impairs the lymphatic system and can lead to the abnormal enlargement of body parts, causing pain, severe disability and social stigma. Ivermectin/albendazole is indicated for the treatment of cases of lymphatic filariasis caused by Wuchereria bancrofti, a parasite which is responsible for 90% of cases worldwide.
==== COVID-19 pandemic ==== In response to the COVID-19 pandemic, most Church's Chicken restaurants closed their dining rooms and continued their drive-thru, counter, takeout and delivery services. In March 2020, company executives announced a franchisee relief plan, where Church's Chicken franchisees could defer 50% of their royalties and ad fund contributions for the next four weeks.
=== Extraterrestrial pathogens === Hoyle and Wickramasinghe have advanced the argument that various outbreaks of illnesses on Earth are of extraterrestrial origins, including the 1918 flu pandemic and certain outbreaks of polio and mad cow disease. For the 1918 flu pandemic they hypothesised that cometary dust brought the virus to Earth simultaneously at multiple locations—a view almost universally dismissed by external experts on this pandemic. On 24 May 2003 The Lancet published a letter from Wickramasinghe, jointly signed by Milton Wainwright and Jayant Narlikar, in which they hypothesised that the virus that causes severe acute respiratory syndrome (SARS) could be extraterrestrial in origin instead of originating from chickens. The Lancet subsequently published three responses to this letter, showing that the hypothesis was not evidence-based, and casting doubts on the quality of the experiments referenced by Wickramasinghe in his letter. Claims connecting terrestrial disease and extraterrestrial pathogens have been rejected by the scientific community. In 2020, Wickramasinghe and colleagues published a paper claiming that Severe acute respiratory syndrome coronavirus 2, the virus responsible for the COVID-19 pandemic was also of extraterrestrial origin, the claim was criticised for lacking evidence.
== Initial investigations == Concerns about an increase in infant collapses and deaths in the neonatal unit at the Countess of Chester Hospital first arose in June 2015, when four collapses occurred, three of them fatal. The unit normally recorded two or three deaths a year. The unit manager, Eirian Powell, and unit lead clinician Brearey carried out an informal review and reported the incidents to the trust's serious‑incident committee, which classified the deaths as medication errors. Brearey noted that Letby had been on duty for each incident but regarded this as an unsurprising coincidence, given staffing levels. He later told the statutory inquiry that no concerns had been raised about her practice at the time. Subsequent reporting in 2023 indicated that he had developed suspicions earlier and believed the trust failed to act on them. A Care Quality Commission inspection in February 2016 heard concerns about difficulties raising issues with managers but was not informed of an elevated mortality rate. Its report highlighted staffing and skill‑mix problems but described a generally positive organisational culture. In May 2016, the trust's executive team concluded that the rise in deaths was coincidental. National MBRRACE‑UK data later showed that the unit's neonatal death rate between June 2015 and June 2016 was at least 10 per cent higher than expected, with deaths in 2015 double those of the previous year. On 24 June 2016, following two further deaths, Brearey asked the duty executive to remove Letby from clinical duties, but was told she was safe to work.
Sources: en.wikipedia.org
=== GABAergic signaling === One mechanism through which BDNF appears to maintain elevated levels of neuronal excitation is through preventing GABAergic signaling activities. While glutamate is the brain's major excitatory neurotransmitter and phosphorylation normally activates receptors, GABA is the brain's primary inhibitory neurotransmitter and phosphorylation of GABAA receptors tend to reduce their activity. Blockading BDNF signaling with a tyrosine kinase inhibitor or a PKC inhibitor in wild type mice produced significant reductions in spontaneous action potential frequencies that were mediated by an increase in the amplitude of GABAergic inhibitory postsynaptic currents (IPSC). Similar effects could be obtained in BDNF knockout mice, but these effects were reversed by local application of BDNF. This suggests BDNF increases excitatory synaptic signaling partly through the post-synaptic suppression of GABAergic signaling by activating PKC through its association with TrkB. Once activated, PKC can reduce the amplitude of IPSCs through to GABAA receptor phosphorylation and inhibition. In support of this putative mechanism, activation of PKCε leads to phosphorylation of N-ethylmaleimide-sensitive factor (NSF) at serine 460 and threonine 461, increasing its ATPase activity which downregulates GABAA receptor surface expression and subsequently attenuates inhibitory currents.
=== United States === On 7 February, a US Marine; Lance Cpl Chukwuemeka E. Oforah, fell overboard the USS Iwo Jima. After a search-and-rescue operation was intiated with no body recovered, he was declared dead on 10 February. He is the first known American fatality from Operation Southern Spear.
One potential scenario that has been envisioned is out-of-control self-replicating molecular assemblers in the form of gray goo which consumes carbon to continue its replication. If unchecked, such mechanical replication could potentially consume whole ecoregions or the whole Earth (ecophagy), or it could simply outcompete natural lifeforms for necessary resources such as carbon, ATP, or UV light (which some nanomotor examples run on). However, the ecophagy and 'grey goo' scenarios, like synthetic molecular assemblers, are based upon still-hypothetical technologies that have not yet been demonstrated experimentally.
==== Metabolism ==== Pregabalin undergoes little or no metabolism. In experiments using nuclear medicine techniques, it was revealed that approximately 98% of the radioactivity recovered in the urine was unchanged pregabalin. The main metabolite is N-methylpregabalin. Pregabalin is generally safe in patients with liver cirrhosis.
Sources: en.wikipedia.org
== Clinical significance == The joint space equals the distance between the involved bones of the joint. A joint space narrowing is a sign of either (or both) osteoarthritis and inflammatory degeneration. The normal joint space is at least 2 mm in the hip (at the superior acetabulum), at least 3 mm in the knee, and 4–5 mm in the shoulder joint. For the temporomandibular joint, a joint space of between 1.5 and 4 mm is regarded as normal. Joint space narrowing is therefore a component of several radiographic classifications of osteoarthritis. In rheumatoid arthritis, the clinical manifestations are primarily synovial inflammation and joint damage. The fibroblast-like synoviocytes, highly specialized mesenchymal cells found in the synovial membrane, have an active and prominent role in the pathogenic processes in the rheumatic joints. Therapies that target these cells are emerging as promising therapeutic tools, raising hope for future applications in rheumatoid arthritis.
=== Classification === Epulis (literally, 'on the gingiva') is a general term for any gingival or alveolar tumor (i.e. lump on the gum). This term describes only the location of a lump and has no implication on the histologic appearance of a lesion. Epulis is also sometimes used synonymously with epulis fissuratum, however other conditions are classified as epulides, e.g. giant cell epulis (peripheral giant cell granuloma), ossifying fibroid epulis (peripheral ossifying fibroma), and congenital epulis.
==== HKUST-1 ==== HKUST-1 consists of a dimeric Cu-paddlewheel that possesses two pore types. Under pelletization MOFs such as HKUST-1 exhibit a pore collapse. Although most carboxylate MOFs have a negative thermal expansion (they densify during heating), it was found that the hardness and Young's moduli unexpectedly decrease with increasing temperature from disordering of linkers. It was also found computationally that a more mesoporous structure has a lower bulk modulus. However, an increased bulk modulus was observed in systems with a few large mesopores versus many small mesopores even though both pore size distributions had the same total pore volume. The HKUST-1 shows a similar, "hyperfilling" phenomenon to the ZIF structures under hydrostatic loading.
In the second case, a biosynthetic pathway needs to be engineered, for example, an E. coli strain that biosynthesizes a novel amino acid (p-aminophenylalanine) from basic carbon sources and includes it in its genetic code. Another example is the production of phosphoserine, a natural metabolite, which required alteration of its pathway flux to increase its production.
=== Selection for Tavistock === In March 1965, Heseltine applied to be candidate for the safe Conservative seat of Tavistock in Devon, where the incumbent MP had announced his retirement two months earlier. Of the 51 applicants, 14 were considered, six of whom had local connections. Heseltine reached the final short list of three, the others being a dairy farmer in a senior position at the Milk Marketing Board (thought to be the favourite), and a local authority lawyer, who later recalled that on the train down from London Heseltine kept jumping out at every stop to check that his magazines were on display at the station newsagents. Heseltine had already spent several days driving round talking to locals and had ordered a year's worth of back copies of Tavistock's two weekly papers. Such effort is nowadays common in Parliamentary selections but was unusual at the time. He was selected by a clear majority of the Tavistock Conservative Association's Finance and General Purposes Committee (which contained between 100 and 120 people). Heseltine was picked in part as a young, dynamic candidate who could face the challenge of the resurgent Liberal Party in the West Country, where Jeremy Thorpe, Peter Bessell and Mark Bonham Carter had recently won seats. The Liberals had halved the Conservative majority at Tavistock in 1964. Trouble then arose at his adoption by a full general meeting of the Conservative Association, which should have been a formality.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.